New Survival Data Keeps Roche Ahead In TIGIT Immunotherapy Race

But Can It Really Challenge Keytruda Dominance?

 
• By Andrew McConaghie

Roche’s Phase II lung cancer results bode well for SKYSCRAPER readout expected in 2022.

Roche_Basel
Despite being a leader in cancer, Roche is still trailing Merck & Co's dominant position in immunotherapy. • Source: Roche

More from Business

More from Scrip